Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q3 2019 Earnings Presentation
9 slides from Puma Biotechnology's earnings presentation, Nov 6, 2019
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update November 6, 2019 Copyright 2019 Puma Biotechnology
Slide 2: Forward-Looking Safe Harbor Statement
Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward–looking statements and are based on the cur
Slide 3: Puma's Pharmacy and Distributor Network
Puma’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network Acaria Health Patients Accredo CVS Onco360 Diplomat Sites of Care Biologics Academic Community Hospitals Hospitals Specialty Distributor Physician Network Other (VA, DoD) Practices McKesson ASD / Oncology Supply Cardinal
Slide 4: $53.5 Million Net Revenue in Q3 2019
$53.5 Million Net Revenue in Q3 2019 QUARTERLY NET REVENUE (IN $MM) 61.1 53.8 53.5 52.6 50.8 45.6 36.0 20.1 6.1 Q3 2 0 1 7 Q4 2 0 1 7 Q1 2 0 1 8 Q2 2 0 1 8 Q3 2 0 1 8 Q4 2 0 1 8 Q1 2 0 1 9 Q2 2 0 1 9 Q3 2 0 1 9 Copyright 2019 Puma 4 Biotechnology
Slide 5: From CONTROL Poster Presented at ASCO 2019
From CONTROL Poster Presented at ASCO 2019 Copyright 2019 Puma Biotechnology 5
Slide 6: 18% of Patients in Q3 Started NERLYNX at a Reduced Dose
18% of Patients in Q3 Started NERLYNX at a Reduced Dose PERCENT OF PATIENT STARTS AT REDUCED DOSE 30% 25% 25% 20% 18% 15% 11% 9% 10% 6% 6% 5% 2% 2% 3% 3% 0% 7 7 8 8 8 8 9 9 9 ly) 2 01 2 01 2 01 2 01 2 01 2 01 2 01 2 01 2 01 n O Q 3 Q 4 Q 1 Q 2 Q 3 Q 4 Q 1 Q 2 Q 3 er tob c (O 19 20 4 Q • Reduced Dose
Slide 7: Bottles Sold By Quarter
Bottles Sold By Quarter BOTTLES SOLD BY QUARTER (SP+SD) 6,000 5,538 4,936 5,000 4,799 4,791 4,696 4,452 4,000 3,517 3,000 2,137 2,000 1,650 1,000 675 - Q3-17 Q4-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 Q3-19 Oct 2019 (est) • SP = Specialty Pharmacy Network, SD = Specialty Distributor Network Copyright
Slide 8: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Expected Regulatory Region Partner Approval Australia / SE • March 2019 – Approved in Asia Australia Israel • Q4 2019 Canada • July 2019 – Approved Greater China • November 2019 – Approved in Hong Kong • 1H 2020 – China • 1H 2020 – Taiwan Latin America • Septem
Slide 9: Puma Biotechnology
Puma Biotechnology Earnings Call Commercial Update November 6, 2019 Copyright 2019 Puma Biotechnology